This content was developed and funded by ViiV Healthcare. For Healthcare Professionals only.
These promotional videos discuss ViiV Healthcare products.
UK Prescribing Information for cabotegravir▼/rilpivirine▼ can be found here.
Please read the summary of product characteristics (SmPC) for cabotegravir here before prescribing.
Please read the summary of product characteristics (SmPC) for rilpivirine here before prescribing.
Adverse event reporting information can be found at the end of this webpage.
The Long-acting Debate: Are We Equipped to End the Epidemic?
The Long-acting Discussion: Linking Evidence, Clinical Cases and Care
In two symposia at the 20th European AIDS Conference (EACS) 2025, held between 15th–18th October in Paris, France, leading HIV experts Karine Lacombe, Christoph Spinner, Jonathan Schapiro, Chloe Orkin, and Monica Gandhi discussed how long-acting therapies such as cabotegravir + rilpivirine long-acting (CAB + RPV LA) may transform HIV treatment and prevention. In case you missed these symposia, these videos summarise the key takeaways to help you broaden your understanding of long-acting therapies in HIV care.
Topics covered:
- What can be done to end the epidemic? Understand the challenges we face and learn what tools are available to overcome them.
- Challenging case studies: Explore the unmet needs of patients living with HIV and discover how long-acting injectables (LAI) can support their care.
Speakers:
Karine Lacombe1
Christoph Spinner2
Jonathan Schapiro3
Chloe Orkin4,5
Monica Gandhi6
| Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441. If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market here: https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/ |
NX-GBL-HVX-WCNT-250116 | November 2025
